Bayer Signals Cardiology Push While U.S. Legal Brief Is Postponed
Shares fell 0.9% after a U.S. courtroom calendar prompted Bayer to request a postponement of a brief. With the legal clock reset, the company plans 11 oral presentations at the ESC Congress in Munich, including pooled INFINITY results on Kerendia in patients with and without atherosclerotic cardiovascular disease. Bayer also made its first milestone payment in a collaboration with MustGrow Biologics.